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Aim: Therapeutic efficacy of pulmonary diseases is often limited and drug delivery 
systems offer new solutions to clinical problems. Solid lipid microparticles (SLMs) are 
suggested as systems for the delivery of therapeutics to the lung as, because of their 
size, they are able to deposit into secondary bronchi. Materials & methods: Here, we 
describe two novel different SLMs using chitosan and alginate such as mucoadhesive 
polymers and we also studied their biocompatibility and their effectiveness compared 
with the free drug in controlling senescence and inflammatory processes in cigarette 
smoke extracts. Results: Data reported show that fluticasone propionate (FP)-loaded 
SLMs are more effective than FP alone in controlling oxidative stress. Conclusion: The 
therapeutic approach using FP-loaded microparticles could be a promising strategy 
for the treatment of the chronic inflammatory pulmonary diseases.
First draft submitted: 28 February 2017; Accepted for publication: 3 July 2017; 
Published online: 4 September 2017
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Lung drug delivery is an important field 
of research in the treatment of chronic 
inflammatory pulmonary diseases, includ-
ing asthma and chronic obstructive pulmo-
nary disease (COPD) [1,2]. The latter is a 
chronic inflammatory disease characterized 
by airflow limitation, excessive production of 
mucus and progressive decline of lung func-
tion. The etiology of the disease depends on 
many factors including genetic predisposi-
tion, age, exposure to pollutants and cigarette 
smoke. Cigarette smoke, the major risk factor 
for COPD, leads to excessive production of 
reactive oxygen species that highly contribute 
to the amplification of airway inflammation, 
to the increased senescence processes and to 
reduce corticosteroid responses. In a model 
of epithelial bronchial cells exposed to ciga-
rette smoke extract (CSE), the free form of 
fluticasone propionate (FP) did not counter-
act efficiently some mechanisms involved in 
oxidative and inflammatory processes, while 
the FP entrapped into nanostructured lipid 
carriers was able to better control oxidative 
stress [3–6]. In this regard, it has been previ-
ously demonstrated that the CSE increased 
both markers of inflammation and mark-
ers of cell senescence including survivin 
 expression in bronchial epithelial cells [7].
Inhalation of drugs by respiratory route 
is still widely used for the treatment of vari-
ous lung diseases. The benefits of inhalation 
therapy include the reduction of side effects 
as a result of the decreased systemic action. 
The effectiveness of a formulation for inhala-
tion depends mainly from its characteristics 
in terms of size and adhesion to the bronchial 
walls [8]. The aerodynamic diameter plays 
a fundamental role in the performance of 
an appropriate formulation for pulmonary 
administration.
Drug delivery systems provide new solu-
tions to clinical problems, particularly in pul-
monary diseases, favoring better delivery of 
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therapeutics to disease sites [9,10]. Pulmonary delivery 
is carried out in different ways: metered dose inhaler 
systems, powders (dry powder inhalers) and solutions 
(nebulizers), which may contain nanostructures such 
as micelles, liposomes, nanoparticles or microstruc-
tures such as microparticles or microemulsions [11,12]. 
Considering that particles with larger diameters (usu-
ally >10 μm) are suitable to deposit in the oropharynx, 
whereas smaller particles (usually <0.5 μm) are easily 
exhaled, the microparticles in the range of 1–5 μm 
represent the best systems to achieve efficacious pul-
monary deposition [13]. In particular, solid lipid mic-
roparticles (SLMs) are adequate systems for inhalation, 
as they would be able to reach directly the bronchial 
epithelium due to their biocompatibility and aerody-
namic diameter (1–5 μm). Consequently, the SLMs, 
depositing in the bronchial area, would avoid the drug 
passage in the alveolar region, and therefore, they 
could reduce the first-pass metabolism and systemic 
toxicity of the drug [14]. Furthermore, to prolong the 
drug action into the lung, mucoadhesive polymers have 
been explored for pulmonary drug delivery applica-
tion. They have structures and functional groups with 
high affinity for mucosal surface [15]. In particular, 
chitosan, a cationic polysaccharide, is one of the most 
studied cationic polymers and it is widely used in phar-
maceutical formulations, pure as well as in derivatized 
form. Chitosan-free amino groups are responsible for 
positive charge (ζ-potential value), which might ensure 
the electrostatic interactions with the anionic groups of 
the mucus. Moreover, alginate, an anionic polysaccha-
ride, is also widely used to obtain mucoadhesive drug 
delivery systems, thanks to its strong ability to form 
hydrogen bonds with mucin layer of mucosa [16,17].
The aim of the present study was to prepare and 
characterize novel muchoadhesive polymer-coated 
SLMs with suitable characteristics for the pulmonary 
delivery of drugs to treat COPD.
Materials & methods
Materials
FP was purchased from Molekula (Rimini, Italy).
Chitosan oligosaccharide lactate (average Mw: 
5000 Da), pluronic F-68 (polyoxyethylene–polyoxy-
propylene block copolymer), dimethyldioctadecyl-
ammonium bromide, sodium alginate, SDS, mucin 
from porcine stomach (III type) and acetonitrile (grade 
HPLC) were purchased from Sigma-Aldrich (Milan, 
Italy). Dichloromethane for HPLC was obtained from 
Merck (Germany). Glycerol tripalmitate (98%) was 
purchased from Alfa Aesar (Germany). Precirol ATO 
5 (glyceryldistearate) was a gift sample from Gattefossè 
(France). Epikuron 200 (soybean lecithin) was a gift 
sample from Lucas Meyer Company (Germany).
Calcium chloride dried (granular) was obtained 
from Carlo Erba Reagenti Srl (Italy).
Phosphate-buffered saline (PBS; without calcium and 
magnesium salt) pH 7.4 (1x) was purchased from Gibco 
by Life Technologies (Gibco, Thermofisher, Italy).
Preparation of chitosan SLMs containing FP
Empty and FP-loaded microparticles (e-chit-SLMs 
and FP-chit-SLMs) were prepared using ethanolic 
precipitation technique. Briefly, glycerol tripalmitate 
(180 mg) was heated at 5–10°C above its melting point 
(m.p. 60–64°C). For obtaining drug-loaded micropar-
ticles, FP (30 mg; m.p. 272–273°C) was added, under 
mechanical stirring, to the melted lipid phase. An eth-
anolic solution (2 ml) of Epikuron 200 (50 mg) was 
then added to the melted lipid phase containing FP 
and the resulting organic solution was dispersed into 
the hot (80°C) bidistilled water (50 ml) containing 
chitosan oligosaccaride lactate 0.1% (w/v) and stirred 
by using an Ultraturrax T125 (IKA Labortechnik, 
Germany) at 21,500 rpm for 2 min. The preoptimized 
microparticles were then subject to a following high-
pressure homogenization by using an High Pressure 
Lab Homogenizer (LM10 Microfluidizer®, Micro-
fluidics, CA, USA) for 2 min at 10,000 psi and the 
obtained emulsion was quickly cooled in an ice bath 
for 30 min.
Finally, the microparticles were purified by exhaus-
tive dialysis (dialysis tube with 12,000/14,000 Dalton 
cutoff, Spectra/Por®, USA) and freeze-dried by using 
a lyophilizer (FreeZone® 4.5 Freeze Dry System, Lab-
conco Corporation, MO, USA) and stored at room 
temperature for successive characterization.
Preparation of alginate SLMs containing FP
Empty and FP-loaded microparticles (e-alg-SLMs and 
FP-alg-SLMs) were prepared using ethanolic precipi-
tation technique followed by ultraturrax homogeniza-
tion. First of all, we prepared a colloidal dispersion of 
cationic solid lipid nanoparticles (cSLNs), which was 
successively coated with an aqueous solution of sodium 
alginate in order to obtain the SLMs.
Briefly, 118 mg of Precirol ATO was heated at 
5–10°C above its m.p. (56°C). For obtaining drug-
loaded nanoparticles, FP (30 mg; m.p. 272–273°C) 
was added, under mechanical stirring, to the melted 
lipid phase. An ethanolic solution (2 ml) containing 
Pluronic F68 (200 mg) and the cationic surfactant 
dimethyldioctadecyl-ammonium bromide (30 mg) 
was then added to the melted lipid phase. Finally, the 
resulting warm organic solution was dispersed into the 
bidistilled water (100 ml) at 80 ± 1°C and homoge-
nized by Ultraturrax T25 at 17,500 rpm for 10 min. 
Then, the emulsion was quickly cooled using an ice 
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bath for 30 min. The colloidal dispersion was purified 
by exhaustive dialysis as above reported.
Afterward, in order to prepare SLMs, the obtained 
cSLNs were coated with sodium alginate by incubating 
them with an aqueous solution of the linear anionic 
polymer (1% w/v) under mechanical stirring, using a 
cSLNs: sodium alginate ratio of 1:8 (w/w). The SLMs 
suspension was kept under stirring for 30 min and then 
centrifuged at 40,000 rpm at 4 ± 1°C for 50 min. The 
supernatant was discarded, while the pellet, consist-
ing of microparticles, was resuspended in a calcium 
chloride aqueous solution (0.5 mM) and kept under 
stirring for 15 min, in order to allow the cross-linking 
of the polymer and its simultaneous deposition on the 
particles surface. The lyophilized powder, obtained as 
described above, was stored at room temperature for 
further characterization.
Particle size analysis
The hydrodynamic diameter (z-average) of the nano- 
and microsuspensions was investigated by photon cor-
relation spectroscopy by using a Zetasizer NanoZS 
(Malvern Instrument Ltd., UK) as reported in the 
literature [17,18]. The samples were diluted until the 
appropriate concentration and then the measurements 
were performed at 25 ± 1°C, at a fixed angle of 173° 
noninvasive backscattering detection in respect to 
the incident beam. Bidistilled water, isotonic aque-
ous solution (NaCl 0.9% w/v) and PBS solution at pH 
7.4 were used as suspending media. The instrument 
setting conditions were: μ = 0.902, refractive index 
(RI) = 1.331; and μ = 0.980, RI = 1.334 when the mea-
surements were carried out in NaCl 0.9 wt% or PBS 
at pH 7.4, respectively. The results of light scattering 
experiments are given as average values obtained using 
samples from three different batches. Each sample was 
measured in triplicate.
ζ-potential measurements
ζ-potential is a measure of the magnitude of the elec-
trostatic or charge repulsion/attraction between parti-
cles, and is one of the fundamental parameters known 
to affect stability. It determines, under the influence 
of an applied electric field, the electrophoretic par-
ticle migration, from which the ζ-potential can be 
 calculated.
In this regard, the analysis was performed at 25 ± 1°C 
using the samples appropriately diluted in the same 
media used for the size measurements. The instrument 
setting conditions were equal to those described above 
for size measurements. The results of these experiments 
are given as average values obtained using samples from 
three different batches. Each  sample was measured in 
triplicate.
Scanning electron microscopy analysis
The morphological analysis of the particles was per-
formed by using an ESEM FEI Quanta 200F scan-
ning electron microscope. The batches in aqueous 
dispersion were deposited directly on a stainless steel 
stub. The water was evaporated at room temperature 
to obtain a dry powder that was sputter-coated under 
vacuum with gold prior to microscopy analysis.
In vitro mucoadhesion test
The mucoadhesiveness of microparticles was evaluated 
using the apparatus previously described in the litera-
ture [19]. A hydrophilic membrane (cellulose nitrate 
membrane, 0.45 μm pore size) was first soaked for 2 h 
in an aqueous mucin solution (0.1% mucin from por-
cine stomach, Type III). Then, 2 ml of FP-alg-SLMs 
(1 mg/ml) or 2 ml of FP-chit-SLMs (2.5 mg/ml) was 
applied dropwise at the core of the membrane. Succes-
sively, the membrane was immediately washed with a 
continuous flow of saline phosphate buffer solution for 
5 min at a rate of 10 ml/min and then dried under vac-
uum. The amount of adhered particles was determined 
by the weight difference between the mucin soaked 
membrane, previously dried and used as control, with 
the microparticles loaded membrane [20]. Experiments 
were performed in triplicate.
Turbidimetric evaluation
The mucoadhesive properties of SLMs were evaluated 
comparing the absorbances at 500 nm of the native 
mucin and different aqueous dispersion obtained incu-
bating, up to 6 h, the SLMs with the native mucin. The 
measurements were performed at 37 ± 1°C by using 
an UV-1800 double beam spectrophotometer (UV-
1800, Shimadzu, Kyoto, Japan). In particular, SLMs 
at different concentrations (from 0.25 to 1 mg/ml) 
were incubated with a native mucin solution (0.1%, 
w/v) using a 1:1 (v/v) ratio. The increase in turbidity 
of mucin SLM dispersions indicated mucoadhesive 
 properties.
HPLC analysis
An adequate HPLC method was developed to study 
loading capacity (LC%) from drug-loaded SLMs 
(FP-chit-SLMs and FP-alg-SLMs). The HPLC anal-
ysis was performed at room temperature by using 
the instrument HPLC, previously described in our 
work [21]. A mixture of acetonitrile/water 65/35 (v/v), 
with a flow rate of 1.2 ml/min, was used as mobile 
phase with an isocratic method. The drug peak was 
measured at wavelength of 238 nm and quantitatively 
determined by comparison with a standard curve 
obtained using FP organic solutions in a mixture of 
dichloromethane/acetonitrile 3/2 (v/v) at known con-
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centrations (tr = 7.00 min). The straight-line equation 
was: y = 50142x + 239223 and the linear regression 
value was: r2 = 0.9967. The linearity of the method 
was studied for FP concentrations in the range of 
10–100 μg/ml.
In order to ensure that the drug was not absorbed 
within the PTFE filters, several FP organic solutions at 
known concentrations were filtered and the concentra-
tions values, before and after filtration, were evaluated 
by HPLC analysis. No significant differences in drug 
concentrations were evidenced.
Drug loading & entrapment efficiency 
determination
Drug loading capacity (DL%), expressed as weight per-
cent (wt%) ratio between entrapped FP and the total 
dried sample weight, was determined by solubilizing 
the FP-chit-SLMs and FP-alg-SLMs into an organic 
mixture (dichloromethane/acetonitrile 3/2 [v/v]) that 
were successively filtered with 0.45 μm polytetrafluo-
roethylene (PTFE) syringe filters (Puradisc Whatman) 
and analyzed by the HPLC method described above. 
The DL% was calculated according to the following 
equation, where W
drug
 represents the amount of FP 
entrapped inside the particles and W
SLMs
 represent the 
weight of the drug-loaded microparticles:
DL
W
W
x
drug
SLMs
(%) = 100
The results are given as average values obtained 
using samples from three different batches and are 
expressed as percentage of FP amount contained in 
100 mg of dried material (LC%).
Moreover, the entrapment efficiency (EE%), 
expressed as wt% ratio between entrapped FP and 
total amount of FP used to prepare the particles, was 
determined according to the following equation, where 
Wf represents the amount of entrapped drug and Wi 
represents the amount of drug used to prepare the FP-
loaded particles:
EE
Wf
Wi
x(%) = 100
Nebulization of alginate & chitosan SLMs 
containing FP & aerodynamic behavior
The in vitro deposition of FP-chit-SLMs and FP-alg-
SLMs was evaluated using the next-generation impac-
tor (Eur. pH 7.2, Copley Scientific Ltd., Nottingham, 
UK) and the PariSX® air jet nebulizer connected to 
a ParyBoySX® compressor. SLMs were dispersed in 
water and then 2 ml of the dispersion was placed in the 
nebulizer and aerosolized for about 15 min directly into 
the throat of the New Generation Impactor (NGI). At 
the end of the experiment, the drug amount deposited 
in each stage of the impactor and the residual (unde-
livered) were collected, using the organic mixture 
(dichloromethane/acetonitrile 3/2 [v/v]), in glass vials 
and analyzed by HPLC, as described in the ‘HPLC 
analysis’ section earlier. Mass median aerodynamic 
diameter (MMAD) and geometric standard deviation 
(GSD) values were calculated without including the 
mass deposited in the induction port. The cumula-
tive amount of particles with a diameter lower than 
the stated size of each stage was plotted as a percent-
age of recovered drug versus the cutoff diameter, and 
the MMAD of the particles was extrapolated from the 
graph according to the European Pharmacopeia [22]. 
The total mass output, which is the percentage of FP 
recovered in the NGI versus the amount of drug placed 
in the nebulizer, the fine particle dose, which repre-
sents the amount of FP contained in droplets of size 
less than 5 μm, and the fine particle fraction (FPF), 
which represents the percentage of droplets with size 
less than 5 μm, were evaluated as well.
FP stability studies in PBS at pH 7.4 containing 
SDS 0.1% (w/v)
FP stability in PBS at pH 7.4 containing 0.1% (w/v) 
SDS was evaluated dispersing 2 mg of FP in 250 ml 
of medium and keeping this suspension at 37 ± 0.1°C, 
under mechanical stirring in a Benchtop 80 ± 0.1°C 
incubator Orbital Shaker model 420. At prefixed time 
intervals, 2 ml was taken out, filtered through 0.45 μm 
cellulose acetate membrane filters (VWR, Milan, Italy) 
and analyzed by the UV spectrophotometer, at 237 nm 
as described above. The peaks areas were compared with 
the one obtained by analyzing standard solutions of FP 
at known concentrations. The straight-line equation 
was: y = 0.033x + 0.0078 and the linear regression value 
was: r2 = 0.9927. The linearity of the method was studied 
for FP concentrations in the range of 2–10 μg/ml.
Release studies of FP in PBS at pH 7.4 
containing 0.1% (w/v) SDS
FP release from both microparticles was studied at 
eight prefixed time intervals. For this purpose, the 
microparticles dispersions (a dispersion for each time 
interval) in PBS at pH 7.4 containing 0.1% (w/v) SDS 
of each batch were prepared maintaining the ‘sink 
conditions.’ The latter refer to the excess solubilizing 
capacity of the dissolution medium (at least three-
times the volume needed to completely solubilize the 
drug). Considering that the FP solubility in the same 
medium, calculated experimentally by UV analysis, 
was 30 μg/ml, the concentrations used for drug release 
were 110 μg/ml for FP-chit-SLMs and 69 μg/ml for 
FP-alg-SLMs (sink conditions). These conditions were 
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Figure 1. Mean size (nm) (A) and zeta potential (B) of empty(e-chit-SLM) and FP-laded chitosan SLM (FP-chit-SLM) 
prepared.
0
500
1000
1500
2000
2500
3000
S
iz
e 
(n
m
)
e-chit-SLM FP-chit-SLM -30
-20
-10
0
10
20
30
40
50
60
e-chit-SLM FP-chit-SLM
Z
et
a 
p
o
te
n
ti
al
 (
m
v)
H2O
NaCl 0.9% (w/v)
PBS pH 7.4
H2O
NaCl 0.9% (w/v)
PBS pH 7.4
Figure 2.  Mean size (nm) (A) and zeta potential (B) of empty and FP-loaded SLN (e-SLN and FP-loaded SLN) and 
alginate SLM (e-alg-SLM and FP-alg-SLM) prepared.
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used to assure that the amount of drug released was not 
limited by the degree of solubility in the buffer or sol-
vent used [23,24]. The prepared dispersions were placed 
into glass tubes suitable for release studies and kept at 
37 ± 0.1°C, under continuous mechanical stirring in a 
Benchtop 80 ± 0.1°C incubator Orbital Shaker model 
420. At prefixed time intervals, aliquots (2 ml) were 
taken out, filtered through 0.45-μm cellulose acetate 
membrane filters (VWR) and analyzed using the 
method described earlier.
Culture of human bronchial epithelial cells
In this study, 16-HBE, an immortalized normal bron-
chial epithelial cell line that retains the differentiated 
morphology and function of normal airway epithelial 
cells, was used [25]. The cells represent a clonal diploid 
(2n = 6) cell line isolated from human lung previously 
used to study the functional properties of bronchial 
epithelial cells in inflammation and repair processes. 
16-HBE cells were maintained in a humidified atmo-
sphere at 37°C and 5% of CO
2
 in air. Cell cultures 
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Figure 3. SEM images of e-chit-SLM (A) and FP-chit-SLM (B), respectively. The bars in the lower right corner 
represent the measurement in μm.
Figure 4.  SEM images of e-alg-SLM (A) and FP-alg-SLM (B), respectively. The bars in the lower right corner 
represent the measurement in μm .
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were cultured as adherent monolayers in Eagle’s mini-
mum essential medium (Gibco, BRL, Germany), sup-
plemented with 10% heat-inactivated (56°C, 30 min) 
fetal bovine serum (Gibco), 1% Eagle’s minimum 
essential medium (nonessential aminoacids; Euro-
clone, Verbania, Italy), 2 mM L-glutamine and 0.5% 
gentamicin (Gibco).
Stimulation of bronchial epithelial cells
Cells were grown in polystyrene flasks 25 cm2 (BD 
Falcon, NJ, USA) for 3 days until 80–90% conflu-
ence. Then, 16-HBE cells were treated in medium 1% 
fetal bovine serum with CSE (20%), and free FP 10-
8 M, FP-alg-SLMs 10-8 M, FP-SLNs 10-8 M, empty-
alg-SLNs (e-alg-SLMs), empty-SLNs. The treatment 
with free or loaded-drug was done 1 h before CSE 
cell stimulation. The time of incubation of CSE was 
20 min to assess the ERK1/2 expression, and 24 h to 
assess the biocompatibility and surviving expression. 
Concentration of CSE and time of incubation were 
selected on the basis of previous findings [26]. At the 
end of stimulation, cells were collected for further 
evaluations. At least three replicates were performed 
for each  experiment.
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Figure 5. Estimation of the interaction betweem FP-chit-SLM and mucin by turbidimetric assay.
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Preparation of CSE
Commercial cigarettes (Marlboro) were used in 
this study. Cigarette smoke solution was prepared as 
described previously [27]. Cigarettes were continuously 
smoked by vacuum pump system. Mainstream smoke 
was drawn through 20 ml of PBS by application of a 
vacuum to the flask containing the PBS. In this way, 
the smoke aspirated by the pump system is solubilized 
in the PBS, generating a CSE–PBS solution. Each ciga-
rette was smoked for 5 min, and two cigarettes were 
used per 20 ml of PBS. The CSE solution was filtered 
through a 0.2-μm polyethersulfone pore filter (Robec-
chi, Nümbrecht, Germany) to remove bacteria and 
large particles. The smoke solution was then adjusted 
to pH 7.4 and used within 30 min of preparation. 
This solution was considered to be 100% CSE and 
diluted to obtain the desired concentration for each 
experiment. The concentration of CSE was calculated 
spectrophotometrically (Beckman Coulter DU-640 
Spectrophotometer), measuring the optical density at 
the wavelength of 320 nm as previously described [26]. 
The pattern of absorbance, among different batches, 
showed very little differences, and the mean optical 
density of the different batches was 1.37 ± 0.16. The 
presence of contaminant lipolysaccharide on undi-
luted CSE was assessed by a commercially available kit 
(Cambrex Corporation, NJ, USA) and was below the 
detection limit of 0.1 EU/ml.
Cell viability assay
Cell viability was evaluated by CellTiter 96 Aqueous 
One Solution Cell Proliferation Assay (PROMEGA, 
WI, USA) according to the manufacturer’s instruc-
tions. One Solution reagent contains (3-(4,5-dimeth-
ylthiazol-2-yl)-5-(3-carboxymethox-yphenyl)-2-(4-
sulfopheyl)2H-tetrazolium). Cells were plated in 
96-well plate and treated for 24 h with free FP, FP-
alg-SLMs, FP-SLNs (10-6, 10-8, 10-10, 10-12 M) after 
drug treatment, 20 ml of One Solution reagent was 
added to each well and cells were incubated for 20 min 
at 37 ± 1°C and 5% CO
2
. The absorbance was read 
at 490 nm using a Microplate reader  wallacVictor2 
1420 Multilabel Counter (Perkin Elmer, Milan, 
Italy). Results are expressed as percentage of viability 
 compared with baseline.
ERK 1/2 expression by Western blot
The pERK1/2 and totERK1/2 expression were 
evaluated by Western blot analysis as previously 
described [28]. An amount of 30 μg of whole cell 
lysates proteins was subjected to SDS-PAGE on 10% 
gels and blotted onto nitrocellulose membranes. The 
following antibodies were used: rabbit anti-pERK1/2 
(9101; Cell Signaling Technology, MA, USA), rabbit 
anti-totERK1/2 (9102; Cell Signaling Technology), 
β-Actin (ACTBD11B7 sc-81178; CA, USA), second-
ary antibodies antirabbit IRDye 680RD (1:15,000; 
LI-COR Biosciences, USA) or antimouse IRDye 
800CW (1:5000; LI-COR Biosciences). The analysis 
was performed at the Odyssey ® CLx Imaging System 
(LI-COR Biosciences, NE, USA).
β-Actin was used as the housekeeping protein to 
normalize protein loading. Signals corresponding of 
the various Western blots were semiquantified by den-
sitometric analysis by using the Image J program, nor-
malized and expressed after correction with the den-
sity of the band obtained for β-actin as pERK/totERK 
ratio.
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Figure 6.  Estimation of the interaction between FP-alg-SLM and mucin by turbidimetric assay.
Mucin dispersion (m) 0.1% (w/v)
FP-alg-SLM 0.25 mg/ml + m
FP-alg-SLM 0.50 mg/ml + m
FP-alg-SLM 0.75 mg/ml + m
FP-alg-SLM 1 mg/ml + m
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Figure 7. Fluticasone propionate dissolution and release profiles from chitosan FP-loaded SLMs and alginate FP-
loaded SLMs in 0.1% SDS in PBS at pH 7.4.
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Survivin expression by flow cytometry
The expression of survivin was evaluated by flow 
cytometry. Flow cytometry analyses were performed on 
a Becton Dickinson FACS Calibur System. The cells 
(16-HBE) were washed twice in PBS and fixed with 
PBS containing 4% paraformaldehyde for 20 min at 
room temperature. After two washes in permeabiliza-
tion buffer (PBS containing 1% FCS, 0.3% saponin 
and 0.1% sodium azide) for 5 min at 4°C were incu-
bated with an antirabbit Survivin (Novus Biologicals, 
CO, USA), followed by antirabbit IgG-FITC (1:350; 
antibodies online) IgG. Analysis was done on 10,000 
acquired events for each sample using cellQuest acqui-
sition and data analysis software (Becton Dickinson, 
Milan, Italy). Negative controls were performed using 
an isotype control antibody (BD PharMingen, CA, 
USA). Data are expressed as percentage of positive cells.
Statistics
Data on survivin expression and pERK/tERK ratio 
10.2217/nnm-2017-0072 
Figure 8. Effects of empty (e-SLN; e-alg-SLM) and FP-loaded (FP-SLN; FP-alg-SLM) nano and microparticles on cell 
viability of bronchial epithelial cells (16HBE). Data represent mean ± S.D. (n=3).
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in 16-HBE were expressed as mean counts ± stan-
dard deviation and were analyzed for the differences 
between different experimental conditions by ANOVA 
with Bonferroni correction. p < 0.05 was considered 
statistically significant.
Results & discussion
Microparticles formulation
The aim of this work was to realize drug delivery systems 
with suitable characteristics for pulmonary administra-
tion of drugs and intended for the treatment of COPD. 
In order to achieve an effective pulmonary deposition, 
circumventing first metabolism and avoiding systemic 
toxicity, microparticles with aerodynamic diameter 
ranging from 1 to 5 μm were obtained. In particular, 
particles with larger diameters (usually >5 μm) are able 
to deposit in the oropharynx, whereas smaller particles 
(usually <0.5 μm) are easily exhaled. Microparticles 
prepared using biodegradable materials are the con-
ventional carriers designed to ensure drug release in 
the lung. Moreover, the use of mucoadhesive polymers, 
allowing SLMs to adhere better to the mucous layer on 
the respiratory epithelium as compared with conven-
tional carriers, represents a good strategy to potentially 
improve the retention, pharmacokinetics and efficacy 
of drugs delivered locally into the lungs [29]. In this 
regard, here we describe the preparation of two differ-
ent kinds of mucoadhesive SLMs, empty and FP-loaded 
and their characterization from the physicochemical, 
 technological and biological point of view.
In order to obtain mucoadhesive microparticles, 
two different biocompatible polymers, chitosan oligo-
saccharide lactate and sodium alginate were used [13,16,30].
The formulations were successfully prepared by 
using the ethanolic precipitation technique, as reported 
in the Materials and Methods section.
Characterization of SLNs & SLMs prepared
Chitosan SLMs, cationic SLNs and alginate SLMs 
were characterized in terms of mean particle size 
and ζ-potential in different aqueous media (bidis-
tilled water, aqueous NaCl 0.9% and PBS solutions). 
Obtained data are reported in Figures 1 & 2.
As shown in Figure 1A, both empty-chit-SLMs 
(e-chit-SLMs) and FP-chit-SLMs showed an average 
particle size in the range between 1500 and 2400 nm 
in all the aqueous media considered.
In particular, in water and NaCl 0.9% (w/v), the 
e-chit-SLMs size was similar because the ζ- potential 
value (+20 mV; Figure 1B) ensured an adequate repul-
sion of particles. Conversely, in PBS at pH 7.4, the 
e-chit-SLMs size was greater because the ζ-potential 
was near zero value (Figure 1B) that could justify a 
size increase. Regarding the FP-loaded SLMs, in both 
saline media, they showed an increase of size due to the 
marked variation of ζ-potential, which did not ensure 
an adequate repulsion and therefore the SLMs seemed 
larger.
Figure 2 shows the particle size (Figure 2A) and the 
ζ-potential (Figure 2B) values of cationic SLNs and algi-
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Figure 9. Effects of emty SLM (e-alg-SLM) and SLN (e-SLN) on survivin expression in CSE exposed cells. 16HBE 
were exposed to CSE 20% in presence and in absence of empty SLN and SLM. Survivin expression was assessed by 
flow cytometry. Data were expressed as % of positive cells (mean ± S.D.) (n = 5).  
•p < 0.05. Representive histograms were shown (B).
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nate SLMs prepared. As can be seen, empty-SLNs and 
FP-SLNs tend to aggregate in aqueous saline media, 
probably due to the high reduction of the ζ-potential. 
On the contrary, e-alg-SLMs and FP-alg-SLMs show 
similar size and comparable ζ-potential values in all the 
media considered. These values assured a good  stability 
of all the aqueous alginate SLMs dispersions.
Scanning electron microscopy analysis
The morphology of the prepared microparticles 
was analyzed by scanning electron microscopy. The 
obtained images are reported in Figures 3 & 4 for chi-
tosan SLMs and alginate SLMs, respectively, and they 
show their shape.
In vitro mucoadhesion test
The microparticles mucoadhesiveness was evaluated by 
examining the adhesion of microparticles on a cellu-
lose membrane soaked with mucin, simulating the pul-
monary epithelia surface, after washing the particles 
applied on the mucous membrane with a saline solu-
tion, as reported in the Experimental section. Under 
these conditions, about 80 wt% of alginate micropar-
ticles remained adherent to the mucus membrane, 
while only 12.4 wt% of chitosan microparticles was 
still adherent after washing. Considering that several 
molecular interactions are involved in the mucoadhe-
sion process (including ionic, hydrogen, van der Waals 
and hydrophobic interactions) and that mucin is a 
highly glycosylated and negatively charged protein, the 
positively charged particles should have much stron-
ger affinity than the negatively charged ones, being 
ionic interactions stronger than hydrophobic interac-
tions [16,31]. Conversely, we obtained the opposite result 
probably due to the direct relationship between the 
chitosan at low molecular weight and its bioadhesive-
ness [15,32,33]. In fact, the molecular weight of chitosan 
had a noticeable influence on the mucoadhesive SLMs 
properties, as widely reported in the literature [34]. 
In this work, the chitosan used was a low-molecular 
weight chitosan and consequently, it was less able to 
create noncovalent bonds with the mucus membrane.
Turbidimetric evaluation
The mucoadhesive interaction between particles and 
mucin results in the adsorption of the mucin around 
the surface of the microparticles and subsequently in a 
slight aggregation that can be detected as an increase 
10.2217/nnm-2017-0072 
Figure 10.  Effects of FP free and FP-loaded SLM (FP-alg-SLM) on survivin expression in CSE exposed cells. 16HBE were exposed 
to CSE 20% in presence and in absence of FP-loade SLN and SLM. Survivin expression was assessed by floe cytometry. Data were 
expressed as % of positive cells (mean ± S.D.) (n = 5).  
•p < 0.05. Representative histograms were shown (B).
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in UV absorbance [35]. For this reason, the turbidity 
value after mixing different aqueous dispersions of chi-
tosan and alginate microparticles with native mucin 
was determined and followed up to 6 h, as reported in 
the literature [36].
As shown in Figures 5 & 6, the turbidity of SLMs/
mucin dispersion was higher than the turbidity of 
mucin dispersion itself at all the concentrations consid-
ered and the greater interactions, for both chitosan and 
alginate microparticles, occurred at the higher concen-
trations of SLMs considered. Moreover, comparing the 
turbidity of chitosan SLMs/mucin and alginate SLMs/
mucin dispersions at 1 mg/ml, the alginate system 
resulted more mucoadhesive respect to the chitosan 
one, in agreement with the in vitro mucoadhesion test 
above reported.
Drug loading determination & release studies 
of FP in PBS at pH 7.4 containing SDS 0.1%
In order to determine the amount of FP entrapped 
into the microparticles, an HPLC analysis was per-
formed as reported in the Materials and Methods 
section. The drug-loading values, expressed as wt% 
ratio between entrapped FP and the total dried sam-
ple weight (DL% w/w), of the systems prepared were 
7.47% for  FP-chit-SLMs and 11.58% for  FP-alg-SLMs, 
 respectively.
The systems were further characterized in terms of 
drug release studies and in vitro biological assays. In 
particular, release studies of FP from FP-chit-SLMs 
and FP-alg-SLMs were carried out in PBS at pH 7.4 
containing SDS 0.1%, as reported in the Materials 
and Methods section. In Figure 7, the released drug, 
expressed as wt% ratio between released drug and the 
total entrapped drug, is reported as a function of incu-
bation time in PBS at pH 7.4 with SDS 0.1%. In the 
same graph, the dissolution profile of FP in the same 
medium is also reported.
By analyzing the data reported in Figure 7, it can 
be said that the solubility of free drug increases over 
time, reaching the maximum value at 6 h and remain-
ing constant up to 48 h. Both systems, FP-chit-SLMs 
and FP-alg-SLMs, showed a similar release profile of 
FP. It was also evaluated that the amount of unre-
leased FP was still inside both microparticles in the 
intact form at every incubation time (data not shown). 
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Figure 11. Effect of SLN and SLM on ERK1/2 expression on bronchial epithelial cells (16-HBE) exposed to cigarette 
smoke. 16-HBE were incubated with CSE 20%, FP free, FP-SLN-alg-SLM 10-8 M. pERK/toERK ratio was evaluated 
by Western blot analysis. (A) Data are expressed as arbitrary units (means  ± S.D.) n = 5).  (B) One out of four 
experiments was shown – beta-actin was used as a housekeeping protein.  
*p < 0.05.
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Results clearly indicate that carriers were able to retain 
about 40 wt% of initially entrapped drug even after 48 
h incubation; therefore, the drug amount not already 
released could be available into bronchial airways after 
this time. Moreover, the drug release profile was not 
influenced by the polymer coating and both systems 
initially showed a burst release of 40 wt% of FP with 
less than 10% more released over the next hours.
Nebulization studies
To evaluate the effectiveness of both formulations as 
pulmonary delivery systems, redispersed SLMs were 
nebulized using the PariSX® air jet nebulizer connected 
to the NGI and the in vitro FP deposition and particle 
aerodynamic diameter were evaluated. The MMAD 
± GSD of FP-alg-SLMs was 3.5 ± 1.3 μm lower than 
that of FP-chit-SLMs, which was 4.0 ± 1.2 μm. It is 
well known that pulmonary drug delivery devices may 
generate different particles with different aerodynamic 
diameter, those with MMAD between 3 and 10 μm 
reach the tracheobronchial region and are generally 
used to treat the airways, while those with MMAD 
between 1 and 3 μm are subjected to systemic drug 
absorption because they reach the alveolar region. 
Particles greater than 5 μm are generally believed 
to deposit in the upper airways (mouth, trachea and 
main bronchi) by inertial impaction, whereas 1–5 μm 
particles are deposited by gravitational settling in the 
 central and distal tract [37].
As previously reported [38], the process of jet nebu-
lization involves repeated cycles of aerosol formation 
and recapture in the nebulizer reservoir before the 
sample leaves the device, during which shearing forces 
are applied to the tested formulations and for this rea-
son the carrier characteristics and stability play a key 
role for its use as a system for pulmonary administra-
tion. The nebulizer content, using both FP-alg-SLMs 
and FP-chit-SLMs, was not completely aerosolized 
being the total mass output 44 and 16%, respectively, 
probably because during the nebulization process 
SLMs aggregated in large particles reducing the effec-
tiveness of the aerosolization. However, it was found 
that for the formulation of FP-alg-SLMs, the FPF% 
was high, 90%, and the fine particle dose 1.13 mg, 
which is predictive of an effective deposition of the 
drug in the furthest stages of the impactor mimicking 
the deepest part of the respiratory tree. FP-chit-SLMs 
provided a high FPF as well (86%), but considering 
that this formulation was poorly aerosolized (16%), 
the actual amount of FP deposited was significantly 
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lower (0.36 mg). Data obtained from this aerosoliza-
tion study suggest that FP-alg-SLMs may represent a 
suitable system for inhalation and drug delivery to the 
deep airways and, thus, the secondary bronchi. Nev-
ertheless, further optimization of the formulation by 
combining SLMs and lactose to obtain a DPI system is 
expected to enhance the performance.
Considering that FP-alg-SLMs had shown better 
characteristics from a technological and physicochemi-
cal point of view than FP-chit-SLMs, for subsequent 
biological studies the alginate systems were chosen. In 
particular, the biological behavior of the FP-alg-SLMs 
was compared with that of cSLNs from which they 
were prepared.
Effects of SLNs & SLMs on cell viability of 16-
HBE cells
For pulmonary application, good tolerability of the 
formulation is an essential precondition [10], since sev-
eral side effects may result from an unsafe material [39]. 
The first step was to assess whether the SLNs and 
SLMs (either empty and FP-loaded) were well toler-
ated by 16-HBE by testing the cell viability at differ-
ent concentrations of entrapped drug (10-6, 10-8, 10-10, 
10-12 M). As shown in Figure 8, the SLNs and SLMs 
(empty and FP-loaded) were well tolerated at all used 
concentrations, evidencing the high biocompatibility 
of obtained micro- and nanoparticles. Based on pre-
liminary experiments, in the subsequent experiments 
empty and FP-loaded SLNs and SLMs were used at 
concentration of 10-8 M.
Effects of empty & FP-loaded SLNs & SLMs on 
survivin expression on 16-HBE cells
Chronic inflammation and cellular senescence (also 
called inflammaging) are deeply involved in the patho-
genesis of premature lung aging, which is considered 
as an important contributing factor in driving COPD. 
Cigarette smoking accelerates the rate of lung function 
decline, inducing damage to proteins and organelles 
by oxidative stress, DNA lesions in pulmonary cells, 
resistance to cell apoptosis, suggesting that smoking 
results in premature aging of the lung [40]. Since senes-
cent cells are characterized by resistance to apoptosis, 
survivin expression was assessed. Survivin is a mem-
ber of the inhibitors of apoptosis protein family, which 
is involved in cell division and inhibits apoptosis by 
directly binding to caspases-3, -7 and -9 and promotes 
cell survival against a variety of apoptotic stimuli. 
Tobacco components can induce survivin expression 
in normal human epithelial cells during early lung 
tumorigenesis [41]. Airway epithelium from smokers 
and smokers-COPD show an increase of expression of 
survivin in comparison to control and CSE increased 
survivin expression in bronchial epithelial cells. Since 
CSE increased survivin expression in bronchial epithe-
lial cells [7], the effect of FP free, empty and FP-loaded 
SLNs, empty and FP-alg-SLMs in CSE-induced sur-
vivin expression was assessed. We confirmed that CSE 
was able to increase survivin expression in 16-HBE 
cells exposed to cigarette smoke. Empty SLNs and 
SLMs (Figure 9A & B) as well as free FP (Figure 10A & B) 
did not significantly affect the CSE-induced survivin 
expression. Otherwise, FP-loaded SLNs and FP-loaded 
SLMs significantly reduced the CSE-induced survivin 
expression (Figure 10A & B).
In this paper, we demonstrated that FP-loaded into 
the particles was able to better control oxidative stress 
probably due to the increased uptake of FP-loaded lipid 
carriers, as reported from the authors in an our pre-
vious paper [3]. Furthermore, we now demonstrate by 
in vitro assays that the increased efficacy of FP could 
be also due to mucoadhesive coating polymer, which 
would allow a better retention time of FP into the 
16-HBE cells. Thereafter, the coating polymer con-
tributes to increase FP efficacy in controlling some 
mechanisms related the senescence processes including 
the  expression of survivin.
Effects of SLNs & SLMs on ERK1/2 ratio 
expression on 16-HBE cells
Airways of patients with COPD are characterized by 
an abnormal chronic inflammatory response of the 
lung induced mainly by cigarette smoke. Cigarette 
smoke activates several MAPK pathways including 
the MEK/Erk1/2 MAPK pathway [42]. Activation of 
Erk1/2 MAPK pathway results in cell survival, prolif-
eration and activation of transcription factor involved 
in inflammatory processes [43]. A substantial body of 
the literature is based on the assumption that CSE is 
able to increase the pERK/totERK ratio in 16-HBE 
cells and here we confirm that CSE was able to increase 
pERK/totERK ratio in 16-HBE cells exposed to ciga-
rette smoke [44]. Moreover, we demonstrate that both 
FP-SLNs and FP-alg-SLMs, but not free FP, were 
able to significantly reduce the effects of CSE on the 
increase of pERK/totERK ratio (Figure 11). In this 
paper, we demonstrate that the increase FP efficacy in 
controlling some mechanisms related the senescence 
processes included the activation of ERK MAPK.
Conclusion
In the present study, we describe the preparation and 
characterization of two novel microparticles with 
mucoadhesive properties for controlled release of FP in 
the treatment of COPD.
The technique used allowed to obtain micropar-
ticles with useful dimensions (MMAD = 3.5–4.0 μM) 
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for pulmonary release of FP to the secondary bronchi, 
avoiding side effects due to a systemic absorption in 
alveolar capillaries, as confirmed by in vitro nebuliza-
tion studies. The alginate coating used for the prepara-
tion of the microparticles allowed to obtain SLMs with 
better mucoadhesive characteristics compared with the 
chitosan SLMs probably due to a formation of a greater 
number of interactions with the components of mucin. 
These results were also confirmed by turbidimetric assay.
The morphological analysis by scanning electron 
microscopy confirmed the micrometer size of the SLMs 
and their shape. Finally, the release studies showed 
that investigated carriers presented a similar release of 
FP and they were also able to retain about 40 wt% of 
initially entrapped drug even after 48 h incubation. 
Therefore, the drug amount not already released could 
be available into bronchial airways after this time.
Furthermore, data herein provided showed that 
the empty microparticles were well tolerated and that 
FP-loaded SLMs were more effective than FP alone 
in controlling events associated to lung inflammag-
ing including ERK1/2 pathway activation and CSE-
induced survivin expression. Since lung inflammaging 
is an important contributing factor in driving COPD, a 
therapeutic approach using FP entrapped into mucoad-
hesive microparticles above described, controlling lung 
inflammaging, could represent a promising  therapeutic 
approach for the disease.
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Summary points
• The preparation and characterization of two novel microparticles (solid lipid microparticles [SLMs]) with 
mucoadhesive properties for controlled release of fluticasone propionate (FP) in the treatment of chronic 
obstructive pulmonary disease is described.
• Mucoadhesive microparticles showed useful mass median aerodynamic diameter (3.5–4.0 μM) for pulmonary 
release of FP to the secondary bronchi, avoiding side effects due to a systemic absorption.
• The alginate coating allowed to obtain SLMs with good mucoadhesive characteristics.
• The morphological analysis by scanning electron microscopy confirmed the micrometer size of the SLMs and 
their shape.
• The release studies showed that the SLMs were able to retain about 40 wt% of initially entrapped drug even 
after 48-h incubation.
• The SLMs were well-tolerated by bronchial epithelial cells (16-HBE).
• The FP-loaded SLMs were more effective than FP alone in controlling events associated with lung 
inflammation including ERK1/2 pathway activation and cigarette smoke extract-induced survivin expression.
• A therapeutic approach using FP entrapped into mucoadhesive microparticles could represent a promising 
therapeutic approach for chronic obstructive pulmonary disease treatment.
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